{
    "clinical_study": {
        "@rank": "156312", 
        "arm_group": [
            {
                "arm_group_label": "Intervention", 
                "arm_group_type": "Experimental", 
                "description": "Dr. Dean Ornish Program for Reversing Heart Disease"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "Non-intervention controls retrospectively matched to intervention participants"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to characterize changes in gene and protein expression in\n      peripheral blood in patients with, or at risk for, heart disease during an intensive\n      lifestyle modification program."
        }, 
        "brief_title": "Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal", 
        "completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Heart Diseases", 
            "Cardiovascular Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This project will use an integrated approach that examines DNA variation and the functional\n      products of genes at both the messenger RNA (mRNA) and protein levels to provide a global\n      view of molecular changes associated with drastic lifestyle modifications designed to\n      reverse coronary heart disease (CHD). DNA variants and/or changes in gene and protein\n      expression associated with CHD reversal may provide important clues to understanding\n      molecular mechanisms of subclinical CHD development and progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosis of coronary artery disease (CAD)\n\n          -  stable angina\n\n          -  angioplasty\n\n          -  evidence of >50% luminal narrowing on coronary angiogram\n\n          -  acute myocardial infarction\n\n          -  bypass surgery\n\n          -  stent placement OR\n\n          -  two or more CAD risk factors\n\n          -  systolic pressure >140 mm Hg or diastolic pressure >90 mm Hg)\n\n          -  high total cholesterol (>200 mg/dL)\n\n          -  physician diagnosed diabetes\n\n          -  body mass index (BMI) >30\n\n          -  family history of heart disease in parents or siblings\n\n          -  21 years of age or older\n\n          -  mentally competent to provide informed consent\n\n        Exclusion Criteria:\n\n          -  known history of autoimmune disease\n\n          -  systemic/chronic disease requiring chemotherapy or long term treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "422", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805492", 
            "org_study_id": "WRI-03-03", 
            "secondary_id": "MDA W81XWH-05-2-0075"
        }, 
        "intervention": {
            "arm_group_label": "Intervention", 
            "description": "Prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Lifestyle intervention consisted of four components: 1) a very low fat vegetarian diet (<10% of calories from fat); 2) 180 minutes/week of moderate aerobic exercise; 3) one hour of stress management each day; and 4) weekly group support sessions.", 
            "intervention_name": "Dr. Dean Ornish Program for Reversing Heart Disease", 
            "intervention_type": "Behavioral"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart diseases", 
            "Cardiovascular diseases", 
            "Lifestyle modification", 
            "Diet", 
            "Exercise"
        ], 
        "lastchanged_date": "March 4, 2013", 
        "link": {
            "description": "Windber Research Institute home page", 
            "url": "http://www.wriwindber.org/"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Windber", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15963"
                }, 
                "name": "Windber Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal", 
        "overall_official": {
            "affiliation": "Windber Research Institute", 
            "last_name": "Darrell L Ellsworth, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Change in BMI from baseline to 12 weeks and from baseline to 52 weeks", 
            "measure": "Change in body mass index", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 12 weeks, 52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805492"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Windber Research Institute", 
            "investigator_full_name": "Darrell L Ellsworth", 
            "investigator_title": "Senior Director, Integrative Cardiac Health Program", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": [
            {
                "PMID": "15539963", 
                "citation": "Ellsworth DL, O'Dowd SC, Salami B, Hochberg A, Vernalis MN, Marshall D, Morris JA, Somiari RI. Intensive lifestyle modification: impact on cardiovascular disease risk factors in subjects with and without clinical cardiovascular disease. Prev Cardiol. 2004 Fall;7(4):168-75."
            }, 
            {
                "PMID": "18197071", 
                "citation": "Vizza J, Neatrour DM, Felton PM, Ellsworth DL. Improvement in psychosocial functioning during an intensive cardiovascular lifestyle modification program. J Cardiopulm Rehabil Prev. 2007 Nov-Dec;27(6):376-83; quiz 384-5. doi: 10.1097/01.HCR.0000300264.07764.84."
            }, 
            {
                "PMID": "19563671", 
                "citation": "Decewicz DJ, Neatrour DM, Burke A, Haberkorn MJ, Patney HL, Vernalis MN, Ellsworth DL. Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy. Lipids Health Dis. 2009 Jun 29;8:26. doi: 10.1186/1476-511X-8-26."
            }, 
            {
                "PMID": "22633795", 
                "citation": "Voeghtly LM, Neatrour DM, Decewicz DJ, Burke A, Haberkorn MJ, Lechak F, Patney HL, Vernalis MN, Ellsworth DL. Cardiometabolic risk reduction in an intensive cardiovascular health program. Nutr Metab Cardiovasc Dis. 2012 May 25. [Epub ahead of print]"
            }
        ], 
        "secondary_outcome": [
            {
                "description": "Change in BP from baseline to 12 weeks and from baseline to 52 weeks", 
                "measure": "Change in blood pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks, 52 weeks"
            }, 
            {
                "description": "Change in HDL-, LDL-, total cholesterol, and triglycerides from baseline to 12 weeks and from baseline to 52 weeks", 
                "measure": "Change in lipids", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks, 52 weeks"
            }, 
            {
                "description": "Change in exercise capacity from baseline to 12 weeks and from baseline to 52 weeks", 
                "measure": "Change in exercise capacity", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks, 52 weeks"
            }
        ], 
        "source": "Windber Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Windber Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2000", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}